JP2018521020A5 - - Google Patents

Download PDF

Info

Publication number
JP2018521020A5
JP2018521020A5 JP2017563311A JP2017563311A JP2018521020A5 JP 2018521020 A5 JP2018521020 A5 JP 2018521020A5 JP 2017563311 A JP2017563311 A JP 2017563311A JP 2017563311 A JP2017563311 A JP 2017563311A JP 2018521020 A5 JP2018521020 A5 JP 2018521020A5
Authority
JP
Japan
Prior art keywords
compound
following formula
pharmaceutically acceptable
acceptable salt
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017563311A
Other languages
English (en)
Japanese (ja)
Other versions
JP6549735B2 (ja
JP2018521020A (ja
Filing date
Publication date
Priority claimed from PCT/IB2015/001693 external-priority patent/WO2016198908A1/en
Application filed filed Critical
Priority claimed from PCT/US2016/036283 external-priority patent/WO2016200851A1/en
Publication of JP2018521020A publication Critical patent/JP2018521020A/ja
Publication of JP2018521020A5 publication Critical patent/JP2018521020A5/ja
Application granted granted Critical
Publication of JP6549735B2 publication Critical patent/JP6549735B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017563311A 2015-06-09 2016-06-08 核内受容体調節剤 Expired - Fee Related JP6549735B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
IBPCT/IB2015/001693 2015-06-09
PCT/IB2015/001693 WO2016198908A1 (en) 2015-06-09 2015-06-09 Ror nuclear receptor modulators
US201562257806P 2015-11-20 2015-11-20
US62/257,806 2015-11-20
US201662343905P 2016-06-01 2016-06-01
US62/343,905 2016-06-01
PCT/US2016/036283 WO2016200851A1 (en) 2015-06-09 2016-06-08 Nuclear receptor modulators

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019118167A Division JP2019178159A (ja) 2015-06-09 2019-06-26 核内受容体調節剤

Publications (3)

Publication Number Publication Date
JP2018521020A JP2018521020A (ja) 2018-08-02
JP2018521020A5 true JP2018521020A5 (cg-RX-API-DMAC7.html) 2019-02-28
JP6549735B2 JP6549735B2 (ja) 2019-07-24

Family

ID=56194583

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017563311A Expired - Fee Related JP6549735B2 (ja) 2015-06-09 2016-06-08 核内受容体調節剤
JP2019118167A Ceased JP2019178159A (ja) 2015-06-09 2019-06-26 核内受容体調節剤
JP2020135558A Expired - Fee Related JP6938737B2 (ja) 2015-06-09 2020-08-11 核内受容体調節剤
JP2021140781A Active JP7235816B2 (ja) 2015-06-09 2021-08-31 核内受容体調節剤

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019118167A Ceased JP2019178159A (ja) 2015-06-09 2019-06-26 核内受容体調節剤
JP2020135558A Expired - Fee Related JP6938737B2 (ja) 2015-06-09 2020-08-11 核内受容体調節剤
JP2021140781A Active JP7235816B2 (ja) 2015-06-09 2021-08-31 核内受容体調節剤

Country Status (36)

Country Link
US (4) US10106501B2 (cg-RX-API-DMAC7.html)
EP (2) EP3307734B1 (cg-RX-API-DMAC7.html)
JP (4) JP6549735B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180014433A (cg-RX-API-DMAC7.html)
CN (1) CN107820494B (cg-RX-API-DMAC7.html)
AU (3) AU2016276316B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017026452A2 (cg-RX-API-DMAC7.html)
CA (1) CA2988502A1 (cg-RX-API-DMAC7.html)
CL (1) CL2017003147A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017012594A2 (cg-RX-API-DMAC7.html)
CR (1) CR20170594A (cg-RX-API-DMAC7.html)
CY (1) CY1122495T1 (cg-RX-API-DMAC7.html)
DK (1) DK3307734T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2017000289A (cg-RX-API-DMAC7.html)
EC (1) ECSP18001225A (cg-RX-API-DMAC7.html)
ES (1) ES2774517T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20200064T1 (cg-RX-API-DMAC7.html)
HU (1) HUE047988T2 (cg-RX-API-DMAC7.html)
IL (2) IL256043B (cg-RX-API-DMAC7.html)
LT (1) LT3307734T (cg-RX-API-DMAC7.html)
MA (1) MA51556A (cg-RX-API-DMAC7.html)
MX (2) MX372543B (cg-RX-API-DMAC7.html)
MY (1) MY193715A (cg-RX-API-DMAC7.html)
PE (1) PE20230683A1 (cg-RX-API-DMAC7.html)
PH (1) PH12017502237B1 (cg-RX-API-DMAC7.html)
PL (1) PL3307734T3 (cg-RX-API-DMAC7.html)
PT (1) PT3307734T (cg-RX-API-DMAC7.html)
RS (1) RS59934B1 (cg-RX-API-DMAC7.html)
RU (1) RU2715897C2 (cg-RX-API-DMAC7.html)
SG (1) SG10201911849SA (cg-RX-API-DMAC7.html)
SI (1) SI3307734T1 (cg-RX-API-DMAC7.html)
TW (2) TW202128619A (cg-RX-API-DMAC7.html)
UA (1) UA120651C2 (cg-RX-API-DMAC7.html)
UY (1) UY36716A (cg-RX-API-DMAC7.html)
WO (1) WO2016200851A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201708285B (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA51556A (fr) * 2015-06-09 2020-11-18 Abbvie Inc Modulateurs du récepteur nucléaire (ror) pour le traitement de maladies inflammatoires et auto-immunes
EP3692991A1 (de) 2015-06-09 2020-08-12 Bayer Pharma Aktiengesellschaft Positiv allosterische modulatoren des muskarinergen m2 rezeptors
GB201609601D0 (en) 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
CA3030204A1 (en) 2016-07-11 2018-01-18 Bayer Pharma Aktiengesellschaft 7-substituted 1-pyridyl-naphthyridine-3-carboxylic acid amides and use thereof
JOP20190045A1 (ar) 2016-09-14 2019-03-14 Bayer Ag مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها.
CN108689942B (zh) * 2017-04-11 2023-06-09 广东东阳光药业有限公司 含氮双环化合物及其制备方法和用途
US11427596B2 (en) * 2019-07-19 2022-08-30 Indian Institute of Technology Indore Metal-free solvent-free synthesis of fused-pyrido heterocycles and biomedical applications
CN110483561B (zh) * 2019-08-24 2021-07-23 中国科学院兰州化学物理研究所 一种烯基硼酸酯类化合物的合成方法
CN110407863B (zh) * 2019-08-24 2021-08-17 中国科学院兰州化学物理研究所 一种通过转移硼化反应合成烯基硼酸酯类化合物的方法
CN114436833B (zh) * 2021-12-27 2024-12-24 南京红太阳医药研究院有限公司 一种替米沙坦关键中间体4′-溴甲基联苯-2-羧酸酯的制备方法
WO2023232870A1 (en) 2022-05-31 2023-12-07 Immunic Ag Rorg/rorgt modulators for the treatment of virus infections like covid-19
AU2024267864A1 (en) * 2023-05-09 2025-11-06 11949098 Canada Inc. Inverse agonists of rar related orphan receptors (rors)
WO2024254218A2 (en) * 2023-06-05 2024-12-12 The Board Of Regents Of The University Of Texas System Non-peptide small molecule fgf14:nav1.6 channel complex protein-protein interaction modulators
CN117263810A (zh) * 2023-09-19 2023-12-22 上海凌凯医药科技有限公司 还原硝基苯制备苯胺类化合物以及选择性碘代苯胺类化合物的方法
CN119241538A (zh) * 2024-09-30 2025-01-03 陕西科技大学 一类三唑并吡啶结构的化合物、合成方法及其应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8641991A (en) 1990-09-10 1992-03-30 Rhone-Poulenc Rorer International (Holdings) Inc. Substituted bicyclic aryl compounds exhibiting selective leukotriene b4 antagonist activity
US5290798A (en) 1991-09-30 1994-03-01 Merck Frosst Canada, Inc. (hetero-arylmethoxy)indoles as inhibitors of leukotriene biosynthesis
ZA928276B (en) 1991-10-31 1993-05-06 Daiichi Seiyaku Co Aromatic amidine derivates and salts thereof.
JP3457694B2 (ja) 1993-02-04 2003-10-20 第一製薬株式会社 インフルエンザ感染予防・治療薬
US5589482A (en) 1994-12-14 1996-12-31 Pfizer Inc. Benzo-thiophene estrogen agonists to treat prostatic hyperplasia
US6124463A (en) 1998-07-02 2000-09-26 Dupont Pharmaceuticals Benzimidazoles as corticotropin release factor antagonists
JP4212358B2 (ja) 2000-12-28 2009-01-21 第一三共株式会社 Vla−4阻害薬
US20070129334A1 (en) 2001-10-30 2007-06-07 Conforma Therapeutics Corporation Orally Active Purine-Based Inhibitors of Heat Shock Protein 90
AU2003220896A1 (en) 2002-03-28 2003-11-10 Sumitomo Pharmaceuticals Co., Ltd. Novel heteroaryl compounds
MXPA05006568A (es) 2002-12-20 2005-09-22 Pharmacia Corp Compuestos de pirazol aciclico para la inhibicion de proteina cinasa-2 activada por proteina cinasa activada por mitogenos.
EP1628970A2 (en) 2003-04-30 2006-03-01 The Institutes of Pharmaceutical Discovery, LLC Heterocycle substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b
KR20060054408A (ko) 2003-07-28 2006-05-22 얀센 파마슈티카 엔.브이. 벤즈이미다졸, 벤즈티아졸 및 벤즈옥사졸 유도체 및lta4 h 조정자로서의 그의 용도
UY28526A1 (es) 2003-09-24 2005-04-29 Boehringer Ingelheim Pharma Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos
US7417063B2 (en) 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
EA200700119A1 (ru) 2004-06-24 2007-10-26 Эли Лилли Энд Компани Соединения и способы лечения дислипидемии
DK1807072T3 (da) 2004-10-29 2009-03-16 Lilly Co Eli Cycloalkyllactamderivater som inhibitorer af 11-beta-hydroxysteroid-dehydrogenase 1
US7855205B2 (en) 2004-10-29 2010-12-21 Janssen Pharmaceutica Nv Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
BRPI0611863B1 (pt) * 2005-06-22 2021-11-23 Plexxikon, Inc Composto, bem como composição e kit compreendendo o mesmo, composto intermediário na preparação do mesmo, método para tratamento e uso do mesmo
FR2890071B1 (fr) 2005-08-30 2007-11-09 Fournier Sa Sa Lab Nouveaux composes de l'indole
EP1994022A2 (en) 2006-03-15 2008-11-26 Wyeth a Corporation of the State of Delaware N-substituted-azacyclylamines as histamine-3 antagonists
US8026257B2 (en) 2007-07-11 2011-09-27 Bristol-Myers Squibb Company Substituted heterocyclic ethers and their use in CNS disorders
ES2524787T3 (es) * 2007-11-15 2014-12-12 Msd Italia S.R.L. Derivados de piridazinona como inhibidores de PARP
WO2010091310A1 (en) 2009-02-06 2010-08-12 Elan Pharmaceuticals, Inc. Inhibitors of jun n-terminal kinase
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
EP2477963A4 (en) 2009-09-18 2013-02-27 Zalicus Pharmaceuticals Ltd ARYLSULFON DERIVATIVES AS CALCIUM CHANNEL BLOCKERS
US20130310379A1 (en) 2010-11-19 2013-11-21 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
US8466186B2 (en) * 2010-12-10 2013-06-18 Boehringer Ingelheim International Gmbh Compounds
EP2487159A1 (en) 2011-02-11 2012-08-15 MSD Oss B.V. RorgammaT inhibitors
EP2736906B1 (en) 2011-07-25 2016-10-19 Allergan, Inc. N-(IMIDAZOLIDIN-2-YLIDENE)-HETEROCYCLOPENTA[b]PYRIDINE DERIVATIVES AS MODULATORS OF ALPHA 2 ADRENERGIC RECEPTORS
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
UA111754C2 (uk) * 2011-10-06 2016-06-10 Байєр Фарма Акцієнгезелльшафт Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань
ES2627347T3 (es) 2011-10-20 2017-07-27 Glaxosmithkline Llc Aza-heterociclos bicíclicos sustituidos y análogos como moduladores de sirtuina
EP2647628A1 (en) 2012-04-02 2013-10-09 Almirall, S.A. Substituted tricyclic compounds with activity towards ep1 receptors
WO2014026328A1 (en) * 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 3-cyclohexenyl substituted indole and indazole compounds as rorgammat inhibitors and uses thereof
US9868748B2 (en) 2013-05-01 2018-01-16 Vitae Pharmaceuticals, Inc. Thiazolopyrrolidine inhibitors of ROR- γ
EP3428160A1 (en) * 2013-08-02 2019-01-16 Pfizer Inc Heterobicycloaryl rorc2 inhibitors and methods of use thereof
CN105531274A (zh) 2013-09-11 2016-04-27 豪夫迈·罗氏有限公司 作为RORc调节剂的酮-咪唑并吡啶衍生物
DK3102576T3 (da) 2014-02-03 2019-07-22 Vitae Pharmaceuticals Llc Dihydropyrrolopyridininhibitorer af ror-gamma
MX371304B (es) 2014-10-14 2020-01-24 Vitae Pharmaceuticals Llc Dihidropirrolopiridinas inhibidoras del receptor huérfano-gamma.
MA51556A (fr) * 2015-06-09 2020-11-18 Abbvie Inc Modulateurs du récepteur nucléaire (ror) pour le traitement de maladies inflammatoires et auto-immunes

Similar Documents

Publication Publication Date Title
JP2018521020A5 (cg-RX-API-DMAC7.html)
JP2017008120A5 (cg-RX-API-DMAC7.html)
JP2018024670A5 (cg-RX-API-DMAC7.html)
JP2019194236A5 (cg-RX-API-DMAC7.html)
JP2012107057A5 (cg-RX-API-DMAC7.html)
JP2017509667A5 (cg-RX-API-DMAC7.html)
JP2018168171A5 (cg-RX-API-DMAC7.html)
JP2014507446A5 (cg-RX-API-DMAC7.html)
JP2017186358A5 (cg-RX-API-DMAC7.html)
JP2014221779A5 (cg-RX-API-DMAC7.html)
JP2019089762A5 (cg-RX-API-DMAC7.html)
JP2013532130A5 (cg-RX-API-DMAC7.html)
JP2018150298A5 (cg-RX-API-DMAC7.html)
JP2020515557A5 (cg-RX-API-DMAC7.html)
JP2012111758A5 (cg-RX-API-DMAC7.html)
JP2014235432A5 (cg-RX-API-DMAC7.html)
JP2018030858A5 (cg-RX-API-DMAC7.html)
JP2015199738A5 (cg-RX-API-DMAC7.html)
JP2011510079A5 (cg-RX-API-DMAC7.html)
JP2013532687A5 (cg-RX-API-DMAC7.html)
JP2018525542A5 (cg-RX-API-DMAC7.html)
JP2011519871A5 (cg-RX-API-DMAC7.html)
JP2016532632A5 (cg-RX-API-DMAC7.html)
JP2017505336A5 (cg-RX-API-DMAC7.html)
JP2016539168A5 (cg-RX-API-DMAC7.html)